- Home
- LCTX vs FMN Comparison
LCTX vs FMN Comparison
Compare LCTX & FMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FMN
- Stock Information
- Founded
- LCTX 1990
- FMN 2002
- Country
- LCTX United States
- FMN United States
- Employees
- LCTX N/A
- FMN N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FMN Investment Managers
- Sector
- LCTX Health Care
- FMN Finance
- Exchange
- LCTX Nasdaq
- FMN Nasdaq
- Market Cap
- LCTX 127.7M
- FMN 127.6M
- IPO Year
- LCTX N/A
- FMN N/A
- Fundamental
- Price
- LCTX $0.61
- FMN $11.18
- Analyst Decision
- LCTX Strong Buy
- FMN
- Analyst Count
- LCTX 5
- FMN 0
- Target Price
- LCTX $4.80
- FMN N/A
- AVG Volume (30 Days)
- LCTX 2.4M
- FMN 22.8K
- Earning Date
- LCTX 03-06-2025
- FMN 01-01-0001
- Dividend Yield
- LCTX N/A
- FMN 3.86%
- EPS Growth
- LCTX N/A
- FMN N/A
- EPS
- LCTX N/A
- FMN N/A
- Revenue
- LCTX $8,719,000.00
- FMN N/A
- Revenue This Year
- LCTX N/A
- FMN N/A
- Revenue Next Year
- LCTX $41.15
- FMN N/A
- P/E Ratio
- LCTX N/A
- FMN N/A
- Revenue Growth
- LCTX N/A
- FMN N/A
- 52 Week Low
- LCTX $0.48
- FMN $9.09
- 52 Week High
- LCTX $1.61
- FMN $11.31
- Technical
- Relative Strength Index (RSI)
- LCTX 52.01
- FMN 59.45
- Support Level
- LCTX $0.55
- FMN $10.78
- Resistance Level
- LCTX $0.60
- FMN $11.19
- Average True Range (ATR)
- LCTX 0.04
- FMN 0.08
- MACD
- LCTX 0.01
- FMN 0.05
- Stochastic Oscillator
- LCTX 83.38
- FMN 97.54
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers.. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.